SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CAMARDA, Valeria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.282
AS - Asia 1.927
EU - Europa 1.079
SA - Sud America 224
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 37
OC - Oceania 3
Totale 8.589
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.191
SG - Singapore 684
CN - Cina 524
VN - Vietnam 219
DE - Germania 212
BR - Brasile 170
UA - Ucraina 170
GB - Regno Unito 163
IT - Italia 161
TR - Turchia 131
HK - Hong Kong 125
FI - Finlandia 97
SE - Svezia 74
FR - Francia 64
CA - Canada 54
BD - Bangladesh 49
IN - India 44
JP - Giappone 43
RU - Federazione Russa 39
MX - Messico 25
PK - Pakistan 22
NL - Olanda 20
PL - Polonia 19
AR - Argentina 18
IQ - Iraq 16
ZA - Sudafrica 15
BE - Belgio 12
CO - Colombia 12
ID - Indonesia 12
ES - Italia 10
LT - Lituania 9
UZ - Uzbekistan 9
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
CL - Cile 6
EC - Ecuador 6
MA - Marocco 6
SA - Arabia Saudita 6
JM - Giamaica 5
MY - Malesia 5
PH - Filippine 5
TH - Thailandia 5
IE - Irlanda 4
VE - Venezuela 4
AU - Australia 3
BG - Bulgaria 3
CH - Svizzera 3
EG - Egitto 3
IL - Israele 3
PY - Paraguay 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BH - Bahrain 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ET - Etiopia 2
IR - Iran 2
KR - Corea 2
KZ - Kazakistan 2
PS - Palestinian Territory 2
RO - Romania 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BZ - Belize 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GE - Georgia 1
HU - Ungheria 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MT - Malta 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
Totale 8.554
Salva come PNG Salva come JPEG
Città #
Dallas 803
Ashburn 477
Fairfield 475
Singapore 464
Woodbridge 431
Houston 252
San Jose 233
Jacksonville 188
Seattle 178
Beijing 175
Chandler 174
Santa Clara 165
Cambridge 161
Ann Arbor 139
Wilmington 136
Hong Kong 124
New York 98
Council Bluffs 84
Los Angeles 77
Munich 70
Nanjing 64
Ho Chi Minh City 63
Izmir 62
San Diego 48
Milan 45
Tokyo 41
Princeton 40
Helsinki 34
Boardman 33
Hanoi 33
Shanghai 33
Lauterbourg 32
London 27
Dong Ket 26
Turku 26
Ferrara 24
Dearborn 22
Bremen 20
Orem 20
São Paulo 20
Addison 16
Brooklyn 16
Buffalo 16
Hebei 16
Mcallen 16
Mexico City 16
Shenyang 16
Toronto 15
Nanchang 14
Warsaw 14
Hefei 13
Auburn Hills 12
Denver 12
Lahore 12
Montréal 12
Philadelphia 12
San Francisco 12
Atlanta 11
Brussels 11
Frankfurt am Main 11
Tianjin 11
Amsterdam 10
Changsha 10
Boston 9
Chicago 9
Falkenstein 9
Haiphong 9
Manchester 9
Norwalk 9
Phoenix 9
Stockholm 9
Baghdad 8
Chennai 8
Da Nang 8
Johannesburg 8
Montreal 8
Charlotte 7
Jiaxing 7
Jinan 7
Moscow 7
New Delhi 7
Ningbo 7
Padova 7
Rio de Janeiro 7
Rome 7
Tashkent 7
Bexley 6
Biên Hòa 6
Guangzhou 6
Las Vegas 6
Mountain View 6
Washington 6
Bologna 5
Dhaka 5
Falls Church 5
Indiana 5
Newark 5
Pittsburgh 5
Poplar 5
Tappahannock 5
Totale 6.179
Salva come PNG Salva come JPEG
Nome #
1,4-Dioxolane-triazaspirodecanone derivatives as nociceptin/orphanin FQ receptor ligands 1.000
Chimeric G proteins in fluorimetric calcium assays: Experience with opioid receptors 348
[Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. 283
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 270
A new ligand for the urotensin II receptor 263
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide 248
Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity 248
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 235
In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant. 230
Pharmacological characterisation of novel kinin B2 receptor ligands 226
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 224
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents 220
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 215
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 215
[Arg(14), Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies 213
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 209
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 207
null 205
Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle 203
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 202
Structure-activity study at positions 3 and 4 of human neuropeptide S. 201
Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors 200
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). 199
Comparative biochemical and pharmacological characterization of a novel, NOP receptor selective hexapeptide, Ac-RYYRIR-ol 191
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11) 190
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5 190
In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1 187
Structure-activity relationship study on human urotensin II 181
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5), DTrp(7), Dab(8)] urotensin II(4-11) (UFP-803) 180
Structure-activity relationship study on Tyr9 of urotensin-II(4-11): Identification of a partial agonist of the UT receptor 178
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors 177
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family 176
The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems 159
Synthesis and Structure-Activity Relationships of (-)-cis-N-Normetazocine-Based LP1 Derivatives 152
Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. 117
Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-Cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4). 116
null 94
null 87
null 78
Synthesis and Structure–Activity Relationships of Triazaspirodecanone Derivatives as Nociceptin/Orphanin FQ Receptor Ligands 72
Totale 8.589
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.802
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.017
Totale 35.819
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022387 0 0 54 5 31 14 31 26 13 41 41 131
2022/2023439 43 26 15 51 79 59 34 35 56 1 21 19
2023/2024266 21 32 15 8 8 59 11 21 3 4 16 68
2024/2025922 35 27 105 23 108 92 23 36 123 74 137 139
2025/20263.287 292 274 782 322 397 190 289 116 199 259 110 57
2026/2027309 82 148 79 0 0 0 0 0 0 0 0 0
Totale 8.589